World Hepatitis Day -July 28, 2014
July 28, 2014, marks the 4th annual World Hepatitis Day. Nearly 400 million persons are living with hepatitis B or hepatitis C, and more than 1 million die annually as a result of their infection. This year, the 67th World Health Assembly (WHA) reaffirmed the global commitment to prevent and control viral hepatitis through the passage of resolution WHA 67.6 (1), which calls for raising public awareness, improving surveillance, strengthening prevention interventions, and increasing access to care and treatment services.
Blood transfusions save lives, and globally more than 100 million units of blood are donated annually. Ensuring access to safe blood is a key strategy for the prevention of hepatitis B and C. In many of the poorest countries of the world, less than 50% of the blood supply comes from voluntary, unpaid donors that were adequately screened for transfusion transmitted infections, including hepatitis B and C.
Prevention and control of hepatitis remains a major challenge in sub-Saharan Africa. This issue of MMWR includes a report from sub-Saharan Africa describing substantial increases in the number of blood units donated and screened for hepatitis B and C during the last decade. Despite these gains, the report demonstrates that the risk for transmission of hepatitis B and C through transfusion persists in many countries in the region. It is estimated that in sub-Saharan Africa, more than 45,000 hepatitis B virus or hepatitis C virus infections are transmitted through contaminated transfusions annually (2) .
Resources and information about World Hepatitis Day are available at http://www.cdc.gov/hepatitis/worldhepday.htm.
HIV/AIDS, Malaria, and Tuberculosis, and the World Health Organization (WHO). Over the last decade, PEPFAR and the Global Fund have supported blood safety programs in many sub-Saharan African countries with heavy burdens of HIV and acquired immunodeficiency syndrome (AIDS), hepatitis, malaria, and maternal mortality. This report summarizes HBV-and HCV-related surveillance data reported by the blood transfusion services of WHO member states to WHO's Global Database on Blood Safety (GDBS) (4) . It also evaluates the performance of blood safety programs in screening for HBV and HCV in 38 sub-Saharan Africa countries. increased, the number of countries screening at least 95% of blood donations for HBV and HCV increased, and the median of the national prevalence of HBV and HCV marker-reactive blood donations decreased. These findings suggest that during the past decade, more blood has been donated and screened for HBV and HCV, resulting in a safer blood supply. Investments in blood safety should be continued to further increase the availability and safety of blood products in sub-Saharan Africa.
Since 1998, WHO member states have submitted blood safety and availability indicators to GDBS. The database contains 49 variables related to blood donations, including screening for HBV, HCV, HIV, and syphilis. Data are selfreported from each country's routine blood collection and testing operations, which typically are conducted at blood transfusion service facilities and then sent to WHO, usually on an annual or biennial basis. At the time of this analysis, GDBS contained data for the following years Table 1 ). The median percentage of anti-HCV marker-reactive donations was 1.4% (31 countries; IQR = 0.6%-3.1%) and 0.9% (36 countries; 
Discussion
This report highlights substantial increases in the number of blood units donated in sub-Saharan Africa, a region known to have blood shortages (5) . It also describes increases in the number of countries testing for HBsAg and HCV antibody, and decreases in the proportion of donations screening positive for markers of HBV and HCV, likely reducing the risk for HBV and HCV infection through blood transfusions in sub-Saharan Africa during the last decade. To reduce the risk for transfusion-transmitted infection and increase the availability of blood, WHO recommends implementation of an integrated and comprehensive strategy based on five key elements: 1) establish a nationally coordinated blood transfusion service, 2) collect blood from regular, voluntary, non-remunerated donors from low-risk populations, 3) test for transfusiontransmissible infections, blood group, and compatibility using quality-assured procedures, 4) reduce unnecessary transfusion through appropriate use of blood, and 5) implement quality systems for the entire transfusion process, from donor recruitment to the follow-up of the recipients of transfusion (5,6). PEPFAR-support for blood transfusion service programs based on WHO recommendations have been shown to reduce the risk for HIV transmission via transfusion while increasing the supply of safe blood (5). However, not all countries are reporting screening at least 95% of their blood donations for HBV and HCV, and high rates of HBV and HCV infection among donors were noted in some countries, indicating continued risk for transfusion recipients. Two previous reports have shown an increase in HIV screening, an increase in donations, and a decrease in the prevalence of HIV-positive donations in African countries (5, 7) . This report demonstrates that many African countries have made similar progress with screening donations for HBV and HCV and decreasing the prevalence of HBV and HCV marker-reactive donations. The epidemiology of HBV and HCV infection is poorly described in sub-Saharan Africa. The findings in this report offer additional data to better understand the burden of HBV and HCV infection in the region. Marker-reactive rates of HBV among blood donors were high, with most countries having rates exceeding 3%; countries of West Africa had particularly high rates, several with rates exceeding 10%. Rates for HCV infection were generally lower, most with rates less than 2%. The risk for developing chronic HBV infection is greatest when infection occurs during birth (up to 90%) and during childhood (30%), and most chronic HBV infection in sub-Saharan Africa is thought to be the result of transmission during birth or childhood (9) . Chronic hepatitis C develops in up to 85% of those who are infected with HCV (9). Coinfection with HIV increases the risk for HBV-and HCV-related liver disease. The risk factors for transmission of HBV and HCV infection in sub-Saharan Africa might include receipt of medical or dental care associated with poor infection control practices, injection drug use, receipt of contaminated blood products, and scarification. Childbirth, inapparent exposures during childhood, and sexual exposure pose a greater risk for HBV than HCV. Because risk factors for transmission of HBV and HCV in sub-Saharan Africa have not been well described, screening by blood collection agencies for recognized risk behaviors, such as injection drug use, might not be as helpful in identifying most cases of chronic HBV or HCV infection in sub-Saharan Africa compared with other parts of the world.
The findings in this report are subject to at least five limitations. First, the data are self-reported by each country and cannot be independently verified. Second, the quality of laboratory screening is not known and might vary within and between countries and between the 2000/2004 and 2010/2011 periods. However, in some PEPFAR countries, efforts to improve the quality of laboratory screening for transfusion-transmissible infections, such as proficiency testing, have been implemented. Third, the data do not represent all health facilities (e.g., private, faith-based, or military facilities) that collect blood outside the national blood transfusion service network. Fourth, countries that had missing data for both years in 2000/2004 or 2010/2011 (four countries for HBV and nine for HCV) were excluded from the comparison of the overall changes in prevalence of HBsAg and anti-HCV reactive blood donations in sub-Saharan Africa. Finally, the screening does not include testing persons for evidence of active HCV infection (i.e., HCV RNA). Improving the quality of laboratory screening of blood for HBV and HCV is only one component in reducing the risk for transfusion-transmitted HBV and HCV. Critical adjuncts to laboratory screening for improved blood safety include 1) targeting outreach and blood collection efforts among populations with low-risk behavioral profiles, 2) collecting blood from regular, voluntary, non-remunerated donors, 3) providing educational materials in donation settings to help infected persons defer themselves from donation (self-deferral) without publicly disclosing their infection status, 4) providing post-donation counselling and referral to care and treatment for blood donors who screen positive for transfusion-transmissible infections, and 5) increasing the proper use of donor history questionnaires to defer persons with high-risk behaviors. Monitoring the prevalence of transfusion-transmissible infections among blood donors is one way to measure the effectiveness of these risk-reduction strategies. Data showing significantly reduced prevalence of laboratory-detected transfusion-transmissible infections suggests improvements in donor recruitment and selection practices.
During the 2010/2011 period, six countries reported high percentages (i.e., 10%-19%) of blood donations to be marker-reactive for HBV, and one country reported a high percentage (i.e., exceeding 5%) of its blood donations to be marker-reactive for HCV. Rates of HBV and HCV markerreactive donations indicate that regional prevalence of chronic HBV and HCV infections remain high among blood donors. Although surveillance of infectious disease rates among blood donors might be of benefit to blood services and public health agencies, reductions in prevalence among blood donors might not be indicative of similar changes among the general population. Despite the progress described in this report, sustained commitment to blood safety programs will be required to further decrease the risk for transfusion-transmitted infections throughout sub-Saharan Africa.
